The MSRB1 antibody targets methionine sulfoxide reductase B1 (MSRB1), an enzyme critical for repairing oxidative damage to methionine residues in proteins. As part of the methionine sulfoxide reductase (MSR) family, MSRB1 specifically reduces methionine-R-sulfoxide back to methionine, counteracting oxidative stress-induced protein dysfunction. This enzyme localizes to mitochondria and the endoplasmic reticulum, playing a key role in cellular antioxidant defense and maintaining protein homeostasis. Dysregulation of MSRB1 has been implicated in aging, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), cardiovascular diseases, and cancer, making it a focus of biomedical research.
MSRB1 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to study the enzyme’s expression, localization, and regulatory roles. Commercial antibodies are available from suppliers such as Abcam, Cell Signaling Technology, and Santa Cruz Biotechnology. Researchers rely on these tools to investigate tissue-specific expression patterns, disease-associated alterations, and MSRB1’s interaction networks. However, variability in antibody performance across applications or sample types necessitates validation via knockout controls or peptide blocking experiments.
Quality control is essential, as batch-to-batch differences can affect specificity. Proper validation ensures accurate detection of the ~12-15 kDa protein and avoids cross-reactivity with other MSR family members. Studies using validated MSRB1 antibodies have advanced understanding of its protective mechanisms in oxidative stress-related pathologies, highlighting its potential as a therapeutic target or biomarker.